What antihypertensive medication regimen is recommended for a patient after a stroke to achieve target blood pressure control?

Blood Pressure Medication Regimen for Post-Stroke Secondary Prevention

After the acute phase of stroke or TIA, initiate an ACE inhibitor combined with a thiazide or thiazide-like diuretic, targeting blood pressure <140/90 mm Hg for most patients, with consideration of <130/80 mm Hg for selected high-risk patients. 1

Target Blood Pressure

• Standard target: <140/90 mm Hg for most post-stroke patients 1, 2
• Lower target: <130/80 mm Hg is reasonable for:
  • Patients with small subcortical stroke 2
  • Patients with diabetes (systolic <130 mm Hg, diastolic <80 mm Hg) 2
  • Very high-risk patients per recent evidence 3, 4

The 2018 Hypertension Canada guidelines provide the most specific and evidence-based targets, with Grade B and C evidence supporting these thresholds. 1 Recent meta-analyses from 2025 confirm that intensive blood pressure control (<130/80 mm Hg) provides superior protection against stroke recurrence compared to standard control (<140/90 mm Hg). 4

Preferred Medication Regimen

First-line therapy: ACE inhibitor + thiazide/thiazide-like diuretic combination 1, 5, 6, 5

This combination has Grade B evidence specifically for post-stroke patients and is the most consistently recommended regimen across multiple Canadian guidelines. 1 The evidence comes primarily from the PROGRESS trial, which demonstrated significant reductions in recurrent stroke with perindopril and indapamide. 7

Alternative Options if ACE Inhibitor Not Tolerated:

• ARB (angiotensin receptor blocker) can substitute for ACE inhibitor 1, 3
• Add thiazide/thiazide-like diuretic to the ARB 1

Additional Agents When Needed:

• Dihydropyridine calcium channel blockers may be added if blood pressure remains uncontrolled 8
• Thiazide diuretics are recommended as additive therapy (Grade D) 1

Critical Contraindication

Do NOT combine ACE inhibitor + ARB in post-stroke patients 1, 5, 6, 5

This combination has Grade B evidence against its use in stroke patients, based on data showing no benefit over ACE inhibitor alone, with increased risks of hypotension, hyperkalemia, and renal impairment. 5 This recommendation is derived from the ONTARGET trial, which included approximately 20% of patients with previous stroke. 5

Timing of Initiation

• Start antihypertensive therapy before hospital discharge after the acute phase (>72 hours post-stroke) 2
• Strong consideration should be given to initiating therapy after the acute phase (Grade A evidence) 8, 1, 5
• Avoid routine blood pressure lowering in the first 72 hours unless extreme elevations occur (SBP >220 mm Hg or DBP >120 mm Hg) 1

Monitoring Requirements

• Frequent monitoring initially (e.g., monthly) until target blood pressure achieved and optimal therapy established 2
• Measure blood pressure routinely, no less than annually, and more frequently based on clinical circumstances 2
• Use proper standardized techniques for office, home, and community testing 2

Special Considerations

For Patients Receiving Thrombolysis:

• Pre-treatment target: <185/110 mm Hg 1
• Post-thrombolysis target for 24 hours: <180/105 mm Hg 1

For Patients with Intracranial Large Artery Atherosclerosis:

• Higher blood pressure targets may be appropriate to maintain cerebral perfusion 3
• Avoid excessive lowering that might exacerbate ischemia in the setting of arterial occlusion 1

For Patients with Chronic Kidney Disease:

• Target <140/90 mm Hg for nondiabetic chronic kidney disease 1
• If proteinuric (>500 mg/24h or ACR >30 mg/mmol), initiate ACE inhibitor or ARB 1

Common Pitfalls to Avoid

1. Precipitous blood pressure drops in acute stroke phase—use agents and routes that avoid rapid decreases 1
2. Combining ACE inhibitor + ARB—this increases adverse events without benefit in stroke patients 1, 5
3. Inadequate follow-up—patients not started on therapy in hospital need arranged follow-up with primary care or stroke prevention service 2
4. Ignoring refractory hypertension—these patients require comprehensive investigation for secondary causes 2

Evidence Quality

The recommendation for ACE inhibitor/diuretic combination has the strongest evidence (Grade B) specifically for post-stroke patients across multiple iterations of Canadian guidelines from 2006-2018. 1, 5, 6, 5 The 2021 AHA/ASA guidelines similarly recommend thiazide diuretics, ACE inhibitors, or ARBs with Grade A evidence for reducing recurrent stroke risk. 3 Recent 2025 meta-analysis data support intensive blood pressure control strategies, showing 13% relative risk reduction in stroke recurrence with targets <130/80 mm Hg. 4